parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in thymic myoid cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 40	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 9303

receipt 9311: IGFN1 in dopamine neurons, braak

power: full sample -0.31 (p 0.204, n 18), 95% CI -0.68 to +0.18. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.31 (p 0.204, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.62 (p 0.0064, n 18). not the mix.
skeptic: leave-one-out range -0.47 to -0.23, sign flips 0; without severely affected donors -0.31 (p 0.204, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for IGFN1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 9310: IGFN1 in astrocytes, braak

power: full sample +0.04 (p 0.881, n 18), 95% CI -0.44 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.00 (p 0.997, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.07 (p 0.787, n 18). could be the mix.
skeptic: leave-one-out range -0.07 to +0.17, sign flips 5; without severely affected donors +0.04 (p 0.881, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for IGFN1 in astrocytes.

case closed: nothing better to follow up.

loading the receipts